Novo Nordisk is committing DKK 8.5bn to a cutting-edge pharmaceutical production site in Odense, Denmark. The 40,000m² facility will feature modular, flexible design for producing rare disease treatments, including haemophilia.
The project emphasizes sustainability, with plans for rooftop solar panels, tree planting, and repurposing materials to create local green spaces, lakes, and forests.
Set for completion in 2027, the site will add 400 permanent jobs. Henrik Wulff, Executive VP, highlights the investment as a step toward meeting global medicine demand while honouring Novo Nordisk’s Danish roots.
Read the full story here.
